China has approved the first brain-computer interface (BCI) device available for use outside clinical trials, offering a potential lifeline to people with severe paralysis caused by spinal cord injuries. The device, called NEO and developed by Neuracle Medical Technology in Shanghai, was authorized by China's National Medical Products Administration last week. It represents a significant milestone for the entire field of brain implant technology, which has long promised to restore function to people with conditions that have no other effective treatments. The NEO device is designed for people aged 18 to 60 with paralysis affecting all four limbs caused by neck-level spinal cord injuries. Unlike some competing brain implants that are inserted directly into brain tissue, the coin-sized NEO sits embedded in the skull with eight electrodes placed over one side of the brain. When a person imagines moving their opposite hand, the device records the electrical signals, sends them to a computer for decoding, and uses that information to control a soft robotic glove. This allows users to perform everyday tasks like eating and drinking that were previously impossible. What Makes This Approval Different From Other Brain Implant Trials? The approval of NEO stands out because it is based on unusually robust long-term evidence. The research team behind the device has collected up to 18 months of data showing that the BCI system works safely and effectively. "That kind of long-term evidence is rare in this field, and I think that's a key reason why this approval was possible," explained Zhengwu Liu, an electrical engineer at the University of Hong Kong who collaborated with the NEO team. This contrasts sharply with other brain implant companies still working through clinical trials. Neuralink, Elon Musk's brain implant company in California, reported in January that 21 people were enrolled in trials of its devices, which began in 2024. Paradromics, a neurotechnology company in Texas, received approval last year to trial a BCI designed to restore speech in people who lost the ability to speak due to neurological diseases and injuries. The key difference is that NEO is less invasive than Neuralink's approach. Neuralink's device is inserted directly into brain tissue, whereas NEO sits on the brain's surface. This less invasive design may have contributed to the faster regulatory approval, according to Avinash Singh, a BCI researcher at the University of Technology Sydney in Australia. How Does the NEO Device Actually Work for Patients? - Signal Recording: Eight electrodes placed over one side of the brain detect electrical activity when a person imagines moving their opposite hand. - Computer Decoding: The recorded signals are sent to a computer that translates the brain signals into commands the robotic glove can understand. - Robotic Control: The decoded signals control a soft robotic glove that allows users to grasp, grip, pinch, and move objects they previously could not manipulate. - Daily Function Restoration: Users can perform essential daily activities such as eating, drinking, and self-care tasks that were impossible before implantation. In one documented case, a person who used the device for nine months was able to eat and drink with their right hand for the first time since their paralysis. Their ability to grasp, grip, and pinch improved significantly, and interestingly, their left hand also showed improvement even though they had not used the glove with that hand. This suggests the brain may be learning and adapting to the technology in ways researchers are still studying. So far, 32 people have received the NEO implant, and all of them have been able to perform grabbing movements with the help of the robotic glove, an action they could not do before the device was implanted. Chen Liang, a neurosurgeon at Huashan Hospital at Fudan University in Shanghai who was involved in the clinical trials, noted that from this perspective, all patients have improved. Why Is This Breakthrough Important for Spinal Cord Injury Patients? The approval of NEO addresses a critical gap in medical treatment. There are currently no effective ways to treat people who have suffered spinal cord injuries, particularly those with paralysis affecting all four limbs. For these patients, a brain implant that can restore even partial function represents a genuine medical breakthrough. The device opens possibilities for improving quality of life in ways that extend beyond the physical. Regaining the ability to feed oneself, drink independently, or perform basic self-care tasks can have profound psychological and emotional benefits for people living with severe paralysis. It also reduces dependence on caregivers for routine daily activities. China's approval also signals that the country views brain-computer interfaces as a future industry with significant potential. This regulatory milestone may accelerate research and development in the field globally, as other countries and companies take note of the successful approval process and the long-term safety data that made it possible. While researchers acknowledge that the study cohort remains small, the approval of NEO represents a turning point. It demonstrates that brain implant technology has matured enough to move from experimental trials into real-world medical practice, offering hope to millions of people worldwide living with paralysis from spinal cord injuries.
